• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    1/26/24 4:25:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    SC 13G/A 1 lilly240086_sc13ga.htm SC 13G/A

     

         
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     
         
     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 39)

     

     

     
      Eli Lilly and Company  
     

     

    (Name of Issuer)

    Common Stock, Without Par Value

     
     

     

    (Title of Class of Securities)

    532457-10-8

     
     

     

    (CUSIP Number)

    December 31, 2023

     
     

     

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

     

    o Rule 13d-1(c)

     

    ü Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

    1 of 5

     

     

    CUSIP No. 532457-10-8 13G  

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

    LILLY ENDOWMENT INC.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

    (b) ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    INDIANA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

    5

    SOLE VOTING POWER

    99,768,810

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    99,768,810

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    99,768,810

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    Not applicable

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.51%

    12

    TYPE OF REPORTING PERSON

    CO

           

    FOOTNOTES:

    The percent of class represented is based on 949,307,237 shares of common stock outstanding as of October 30, 2023, as reported on the Issuer’s Form 10Q for the period ended September 30, 2023.

    2 of 5

     

    Item 1.

    (a)Name of Issuer

    Eli Lilly and Company

     

    (b)Address of Issuer's Principal Executive Offices

    Lilly Corporate Center, Indianapolis, Indiana 46285

     

     

    Item 2.

    (a)Name of Person Filing

    This statement is filed by Lilly Endowment Inc., a not for profit corporation organized under the laws of the State of Indiana. Lilly Endowment Inc is an organization described in Section 50l(c)(3) of the Internal Revenue Code of 1986 and is a private foundation under Section 509(a) of the Code.

     

    (b)Address of Principal Business Office or, if none, Residence

    The address of the principal business office of Lilly Endowment Inc. is 2801 No 11th Meridian Street, Indianapolis, Indiana 46208.

     

     

    (c)Citizenship

    Indiana

     

    (d)Title of Class of Securities

    Common Stock, Without Par Value

     

    (e)CUSIP Number

    532457-10-8

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)o Broker or dealer registered under section 15 of the Act.
         
     (b)o Bank as defined in section 3(a)(6) of the Act.
         
     (c)o Insurance company as defined in section 3(a)(19) of the Act.
         
     (d)o Investment company registered under section 8 of the Investment Company Act of 1940.
         
     (e)o An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).
         
     (f)o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F).
         
     (g)o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
         
     (h)o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
         
     (i)o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
    Investment Company Act of 1940.
         
     (k)o A group, in accordance with§ 240. I 3d-l(b)(l )(ii)(K). If filing as a non-U.S. institution in accordance with§ 240.13d-l(b)(I)(ii)(J), please specify the type of institution.

    3 of 5

     

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned

           99,768,810

     

    (b)Percent of Class

            10.51%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote
         
        99,768,810
         
       (ii) Shared power to vote or to direct the vote
         
        0
         
       (iii)Sole power to dispose or to direct the disposition of
         
        99,768,810
         
       (iv) Shared power to dispose or to direct the disposition of
         
        0

     

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.Notice of Dissolution of Group

    Not Applicable

     

    Item 10.Certification

     

    Not Applicable

    4 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: January 19, 2024 Lilly Endowment Inc.
       
      By: /s/ Diane M. Stenson
      Name: Diane M. Stenson
      Title: Vice President & Treasurer

     

     

    Footnotes: Item 4: This information is provided as of December 31, 2023.
       
      Item 4(a): None of such shares are deemed to be beneficially owned by reason of the possession of Lilly Endowment Inc. of a right to acquire such shares.
       
      Item 4(b): The percent of class represented is based on 949,307,237 shares of common stock outstanding as of October 30, 2023 as reported on the Issuer’s Form 10Q for the period ended September 30, 2023.

    5 of 5 

    Get the next $LLY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    6/5/2025Buy → Hold
    Erste Group
    4/28/2025$1150.00 → $700.00Buy → Reduce
    HSBC Securities
    4/22/2025$975.00Overweight
    Cantor Fitzgerald
    12/10/2024$997.00Buy
    BofA Securities
    11/15/2024$1000.00Outperform
    Wolfe Research
    10/17/2024$1100.00Outperform
    Bernstein
    9/13/2024$1060.00Buy
    Citigroup
    8/12/2024$1025.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sulzberger Gabrielle was granted 6 shares, increasing direct ownership by 0.24% to 2,580 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:28:26 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Luciano Juan R was granted 18 shares, increasing direct ownership by 0.11% to 16,362 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:26:05 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hedley Mary Lynne was granted 12 shares, increasing direct ownership by 0.63% to 1,960 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:23:14 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

      Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve. Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovasc

      6/17/25 6:45:00 AM ET
      $LLY
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

      With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay Journey Program In a clinical trial, adults with obesity or overweight and a weight-related medical condition taking Zepbound 15 mg lost 48 lbs (~21% weight loss) and approximately 1 in 3 on Zepbound 15 mg lost over 58 lbs (25% weight loss) INDIANAPOLIS, June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay

      6/16/25 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

      INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been p

      6/2/25 10:00:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    SEC Filings

    See more
    • SEC Form 11-K filed by Eli Lilly and Company

      11-K - ELI LILLY & Co (0000059478) (Filer)

      6/20/25 4:23:15 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Eli Lilly and Company

      SD - ELI LILLY & Co (0000059478) (Filer)

      5/9/25 4:12:45 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eli Lilly and Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ELI LILLY & Co (0000059478) (Filer)

      5/8/25 4:34:55 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care